Gene · 8291
Papers2,035
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
101 to 120 of 2,035
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Gene-editing in patient and humanized-mice primary muscle stem cells rescues dysferlin expression in dysferlin-deficient muscular dystrophy. | Nat Commun | 2025 | 39747848 | PubTator, text mining | PubMed |
| Syntaxin 4-enhanced plasma membrane repair is independent of dysferlin in skeletal muscle. | Am J Physiol Cell Physiol | 2025 | 39726261 | PubTator, text mining | PubMed |
| Seminal Plasma-Derived Exosome Preserves the Quality Parameters of the Post-Thaw Semen of Bulls with Low Freezeability. | Biopreserv Biobank | 2025 | 39723439 | PubTator, text mining | PubMed |
| Asymptomatic HyperCKemia in the Pediatric Population: A Prospective Study Utilizing Next-Generation Sequencing and Ancillary Tests. | Neurology | 2025 | 39666917 | PubTator, text mining | PubMed |
| Asymptomatic and oligosymptomatic states of dysferlinopathy. | J Neuromuscul Dis | 2024 | 39973465 | PubTator, text mining | PubMed |
| Cryo-EM structures of the membrane repair protein dysferlin. | Nat Commun | 2024 | 39511170 | PubTator, text mining | PubMed |
| Multiple sclerosis and COVID-19: a bidirectional Mendelian randomization study. | Front Immunol | 2024 | 39493765 | PubTator, text mining | PubMed |
| Challenging Diagnosis of a Patient with Two Novel Variants in the SYNE1 Gene. | Int J Mol Sci | 2024 | 39409170 | PubTator, text mining | PubMed |
| Plasma membrane repair defect in Alzheimer's disease neurons is driven by the reduced dysferlin expression. | FASEB J | 2024 | 39400395 | PubTator, text mining | PubMed |
| Clinical Presentation, Diagnosis, and Genetic Insights of Miyoshi Myopathy: A Case Report and Literature Review. | Cureus | 2024 | 39376872 | PubTator, text mining | PubMed |
| Comprehensive Proteomic Analysis of Dysferlinopathy Unveiling Molecular Mechanisms and Biomarkers Linked to Pathological Progression. | CNS Neurosci Ther | 2024 | 39350328 | PubTator, text mining | PubMed |
| Can we differentiate patients with dysferlinopathies and inflammatory myopathies by ultrasound? A discriminant analysis study. | Rheumatol Int | 2024 | 39292434 | PubTator, text mining | PubMed |
| [Clinical and genetic characterisation of hereditary distal myopathies in a series of Colombian patients]. | Rev Neurol | 2024 | 39207128 | PubTator, text mining | PubMed |
| Clinical description of a homozygous Lys 1169* variant in the DYSF gene associated with autosomal recessive Miyoshi muscular dystrophy type 1: A familial case report. | Heliyon | 2024 | 39170343 | PubTator, text mining | PubMed |
| Brain of miyoshi myopathy/dysferlinopathy patients presents with structural and metabolic anomalies. | Sci Rep | 2024 | 39164335 | PubTator, text mining | PubMed |
| Diagnosis of dysferlinopathy masked by a superimposed hypothyroid myopathy. | BMJ Case Rep | 2024 | 39153757 | PubTator, text mining | PubMed |
| Apolipoprotein E knockout, but not cholesteryl ester transfer protein (CETP)-associated high-density lipoprotein cholesterol (HDL-C) lowering, exacerbates muscle wasting in dysferlin-null mice. | Lipids Health Dis | 2024 | 39138561 | PubTator, text mining | PubMed |
| Pilot investigations into the mechanistic basis for adverse effects of glucocorticoids in dysferlinopathy. | Skelet Muscle | 2024 | 39123261 | PubTator, text mining | PubMed |
| Clinical, Histopathologic, and Genetic Features of Patients With Myofibrillary and Distal Myopathies: Experience From the Italian Network. | Neurology | 2024 | 39102614 | PubTator, text mining | PubMed |
| Two homozygous adjacent novel missense mutations in DYSF gene caused dysferlinopathy due to splicing abnormalities. | Front Genet | 2024 | 38903757 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8291/papers?page=6